Press Release

June 2015 - Cranbury, New Jersey — Kenneth Bahrt, MD, FACR has joined Oncobiologics as its Chief Medical Officer.  A recognized expert in immunology, he brings over 30 years of clinical and pharmaceutical industry experience in both small molecule and protein therapeutics.   

Oncobiologics Founder & CEO Pankaj Mohan, Ph.D. commented, “We are thrilled to welcome Ken Bahrt to Oncobiologics as our Chief Medical Officer.   His expertise in immunology is a perfect complement to the oncology expertise of Deputy Medical Officer Dr. Claude Nicaise.  As we advance our clinical biosimilars pipeline, we now have the breadth and depth of medical expertise to successfully navigate the clinical and commercialization process.”

Dr. Bahrt previously served as the Vice President of US Medical Affairs at NPS Pharmaceuticals responsible for two orphan products.  He was part of the launch team for Natpara, the first replacement hormone therapy for hypoparathyroidism.  At Savient Pharmaceuticals, he was SVP and Chief Medical Officer and was the medical lead on the team that obtained European marketing approval for Krystexxa (pegloticase) for the treatment of chronic tophaceous gout.  Previously, Dr. Bahrt joined Genentech as part of the Roche acquisition and became the Therapeutic Head of Immunology Medical Affairs responsible for multiple products including Actrema, Rituxan, Xolair, and Pulmozyme.  While at Roche, he was the Global Medical Director for Immunology, leading both the US and Global Medical Affairs teams.

Dr. Bahrt is a board-certified Internist and Rheumatologist and a Fellow of the American College of Rheumatology.  He has been Chairman of the Industry Roundtable and a member of the Board of Directors for the Research and Education Foundation of the American College of Rheumatology. He has authored or co-authored numerous scientific publications.  Dr. Bahrt holds a medical degree from Hahnemann University and a bachelor’s degree in biology from Muhlenberg College.